

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**For the month of February 2020**

**Commission File Number 001-37410**

**ESSA Pharma Inc.**  
(Translation of registrant's name into English)

**Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

### EXPLANATORY NOTE

The following exhibits included herein were filed by the Registrant with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval on the dates noted below:

1. Exhibit 99.1 News Release date February 27, 2020: ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
2. Exhibit 99.2 Report of Voting Results

This report on Form 6-K shall be incorporated by reference into the registrant's Registration Statements on Form F-3 (File No. 333-222654 and File No. 333-234136) and Form S-8 (File No. 333-225056) under the Securities Act of 1933, as amended.

**EXHIBITS INCLUDED AS PART OF THIS REPORT**

**Exhibit**

- [99.1](#) [News Release Dated February 27, 2020: ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders](#)
- [99.2](#) [Report of Voting Results](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

*ESSA PHARMA INC.*

\_\_\_\_\_  
(Registrant)

Date: February 27, 2020.

By: /s/ DAVID WOOD

Name: David Wood

Title: Chief Financial Officer



## ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

HOUSTON and VANCOUVER, Feb. 27, 2020 /CNW/ - ESSA Pharma Inc. ("**ESSA**" or the "**Company**") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "**Meeting**").

At the Meeting, the shareholders of the Company (the "**Shareholders**") set the number of directors at nine and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, and Ari Brettman to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
David R. Parkinson	13,462,400	99.93%	9,170	0.07%
Richard M. Glickman	13,311,982	98.82%	159,588	1.18%
Gary Sollis	13,462,400	99.93%	9,170	0.07%
Franklin M. Berger	13,311,982	98.82%	159,588	1.18%
Scott Requadt	13,467,900	99.97%	3,670	0.03%
Marella Thorell	13,311,882	98.81%	159,688	1.19%
Alex Martin	13,311,882	98.81%	159,688	1.19%
Sandy Zweifach	13,317,482	98.86%	154,088	1.14%
Ari Brettman	13,311,882	98.81%	159,688	1.19%

At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) an amendment to the Company's existing stock option plan (the "**Amended Option Plan**"); (iii) the previous grant of stock options exercisable for an aggregate of up to 2,766,470 common shares in the Company under the Amended Option Plan; and (iv) an amendment to the Company's existing restricted share unit plan.

### About ESSA Pharma Inc.

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("**AR**"), inhibiting AR driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing IND-enabling studies and expects to file an IND with the US Food and Drug Administration ("**FDA**") for EPI-7386 in the first calendar quarter of 2020. For more information about ESSA, please visit [www.essapharma.com](http://www.essapharma.com) or follow us on Twitter under [@ESSAPharma.com](https://twitter.com/ESSAPharma).

### About Prostate Cancer

Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen

for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease, metastatic CRPC ("mCRPC"), and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.

### **Forward-Looking Statement Disclaimer**

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding the preparation and expected timing of an IND filing with the FDA for EPI-7386 and other statements surrounding the Company's clinical evaluation of EPI-7386.

Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 19, 2019 under the heading "Risk Factors", a copy of which is available on ESSA's profile on the SEDAR website at [www.sedar.com](http://www.sedar.com), ESSA's profile on EDGAR at [www.sec.gov](http://www.sec.gov), and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

View original content:<http://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-301013134.html>

SOURCE ESSA Pharma Inc

View original content: <http://www.newswire.ca/en/releases/archive/February2020/27/c1697.html>

%CIK: 0001633932

**For further information:** Company Contact: David Wood, Chief Financial Officer, ESSA Pharma Inc., Contact: (778) 331-0962, E-mail: [dwood@essapharma.com](mailto:dwood@essapharma.com); Investor Relations Contact: Alan Lada, Solebury Trout, Contact: (617) 221-8006, E-mail: [alada@soleburytrout.com](mailto:alada@soleburytrout.com)

CO: ESSA Pharma Inc

CNW 19:51e 27-FEB-20

**ESSA Pharma Inc. (the “Company”)**  
**Annual General Meeting of Shareholders (the “Meeting”)**

February 27, 2020

**REPORT OF VOTING RESULTS**  
**(Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations)**

Common shares of the Company (the “ <b>Common Shares</b> ”) represented at the Meeting:	16,405,094
Total issued and outstanding Common Shares as at the record date for the meeting:	20,824,339
Percentage of issued and outstanding Common Shares represented:	78.78%

**1. Setting Number of Directors**

By ordinary resolution passed by show of hands, the number of directors for the ensuing year was set at nine.

**2. Election of Directors**

By ordinary resolution passed by ballot vote, the following nine nominees proposed by management were elected as directors of the Company to hold office until the next annual meeting of the shareholders of the Company (the “**Shareholders**”) or until their successors are elected or appointed:

<b>Nominee</b>	<b>Votes For</b>	<b>% Votes For</b>	<b>Votes Withheld</b>	<b>% Votes Withheld</b>
David R. Parkinson	13,462,400	99.93%	9,170	0.07%
Richard M. Glickman	13,311,982	98.82%	159,588	1.18%
Gary Sollis	13,462,400	99.93%	9,170	0.07%
Franklin M. Berger	13,311,982	98.82%	159,588	1.18%
Scott Requadt	13,467,900	99.97%	3,670	0.03%
Marella Thorell	13,311,882	98.81%	159,688	1.19%
Alex Martin	13,311,882	98.81%	159,688	1.19%
Sandy Zweifach	13,317,482	98.86%	154,088	1.14%
Ari Brettman	13,311,882	98.81%	159,688	1.19%

### 3. Appointment of Auditor

By ordinary resolution passed by show of hands, Davidson & Company LLP, Chartered Professional Accountants, was appointed auditor of the Company for the ensuing year.

### 4. Amendment to Existing Option Plan

By ordinary resolution passed by ballot vote, an amendment to the Company's stock option plan (as amended, the "Amended Option Plan") as set out in Schedule A to the Company's management information circular dated January 22, 2020 (the "Circular"), and provided to the Shareholders in connection with the Meeting, was ratified, confirmed, and approved:

Votes by Ballot	Votes For	% Votes For	Votes Against	% Votes Against
By all shareholders	13,441,061	99.77%	30,509	0.23%

### 5. Ratification of Grants under the Amended Stock Option Plan

By ordinary resolution passed by ballot vote, the previous grants of an aggregate of up to 2,776,470 stock options to certain directors, officers, employees and consultants of the Company, under the Amended Option Plan, as further set out in the Circular, and provided to the Shareholders in connection with the Meeting, were ratified, confirmed and approved: 131739610

Votes by Ballot	Votes For	% Votes For	Votes Against	% Votes Against
By all shareholders	13,277,613	98.53%	193,957	1.47%
By disinterested shareholders	12,979,653	98.53%	193,957	1.47%

### 6. Amendment to Existing Restricted Share Unit Plan

By ordinary resolution passed by ballot vote, an amendment to the Company's restricted share unit plan as set out in Schedule B to the Circular, and provided to the Shareholders in connection with the Meeting, was ratified, confirmed, and approved:

Votes by Ballot	Votes For	% Votes For	Votes Against	% Votes Against
By all shareholders	13,723,972	98.50%	197,598	1.50%
By disinterested shareholders	12,976,012	98.50%	197,598	1.50%

No other non-routine business was transacted or voted upon at the Meeting.

**Dated:** February 27, 2020